# 2026-20434: FDA Fast-Tracks Kid Gene Therapy with Special Voucher

2026-20434, Issuance of Priority Review Voucher; Rare Pediatric Disease Product; FAYUVI (rebisufligene etisparvovec-hopf), is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-10-06, effective 2026-09-17; PRIA reads it as touching household money (as of 2026-10-13).

- Canonical: https://policyrisk.com/federal-register/2026-20434
- As of: 2026-10-13
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-20434
- Title: Issuance of Priority Review Voucher; Rare Pediatric Disease Product; FAYUVI (rebisufligene etisparvovec-hopf)
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 63569
- Published: 2026-10-06
- Effective: 2026-09-17
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-10-13

## In one line

FDA Fast-Tracks Kid Gene Therapy with Special Voucher

## Summary

The FDA just gave a special priority review voucher to Ultragenyx for their new gene therapy, FAYUVI, which treats a rare childhood disease called Sanfilippo syndrome type A. This voucher speeds up future drug reviews, helping get important medicines to kids faster. The approval happened on September 17, 2026, marking a big win for rare disease treatments and the company behind it.

## Abstract

The Food and Drug Administration (FDA) is announcing the issuance of a priority review voucher to the sponsor of a rare pediatric disease product application. The Federal Food, Drug, and Cosmetic Act (FD&C Act) authorizes FDA to award priority review vouchers to sponsors of approved rare pediatric disease product applications that meet certain criteria. FDA is required to publish notice of the award of the priority review voucher. FDA has determined that FAYUVI (rebisufligene etisparvovec-hopf), approved on September 17, 2026, manufactured by Ultragenyx Pharmaceutical Inc., meets the criteria for a priority review voucher.

## Effects PRIA read

- Priority Review Voucher Awarded: benefit, medium. The FDA issued a priority review voucher to Ultragenyx Pharmaceutical Inc. for FAYUVI (rebisufligene etisparvovec-hopf) following the product's approval on September 17, 2026. The award was made under section 529 of the Federal Food, Drug, and Cosmetic Act.
- New Gene Therapy Approved for Sanfilippo: benefit, high. FAYUVI (rebisufligene etisparvovec-hopf) was approved on September 17, 2026 for treatment of the neurologic manifestations of mucopolysaccharidosis type IIIA (MPS IIIA, Sanfilippo syndrome type A) in pediatric patients with preserved neurodevelopmental function. Pediatric patients meeting that indi…

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-20434 on federalregister.gov](https://www.federalregister.gov/documents/2026/10/06/2026-20434/issuance-of-priority-review-voucher-rare-pediatric-disease-product-fayuvi-rebisufligene)
- [2026-20434 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-10-06/pdf/2026-20434.pdf)

## Related
- [Previous: 2026-20433, Privacy Act of 1974; System of Records](https://policyrisk.com/federal-register/2026-20433)
- [Next: 2026-20436, Certain New Chemicals or Significant New Uses; Statements of Findings-June 2026](https://policyrisk.com/federal-register/2026-20436)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-20434 (as of 2026-10-13).
